title: Effectiveness of Chinese prescription Kangen-karyu for dyslipi-demia, using 3T3-L1 adipocytes and type 2 diabetic mice.
abstract: The Chinese prescription Kangen-karyu, comprised of six crude drugs, has received much attention due to its numerous biological activities. The present study was conducted to examine whether Kangen-karyu has an ameliorative effect on dyslipidemia. The effect of Kangen-karyu was evaluated using 3T3-L1 adipocytes, and also db/db mice as an experimental model for diabetic dyslipidemia. Kangen-karyu significantly inhibited adipocyte differentiation and lipid accumulation. Kangen-karyu also down-regulated the mRNA levels of peroxisome proliferator-activated receptor (PPAR)γ, sterol regulatory element-binding protein (SREBP)-1c, and fatty acid synthase, and the protein levels of aP2 and PPARγ, which indicates that Kangen-karyu inhibited adipogenesis during adipocyte differentiation, and may have potential anti-dyslipidemia effects. In addition, the administration of Kangen-karyu reduced hyperlipidemia in db/db type 2 diabetic mice through a decline in the serum levels of lipids, and an improvement of lipoprotein profiles. The enhanced hepatic triglyceride level of the db/db mice was significantly reduced by Kangen-karyu administration through the down-regulation of SREBP-1 and lipogenic enzymes in the liver. These findings indicate that Kangen-karyu exerts anti-dyslipidemia effects in adipocytes and type 2 diabetic db/db mice.
authors.affiliation: College of Korean Medicine, Daegu Haany University.
authors.forename: Chan
authors.initials: C
authors.lastname: Hum Park
authors.forename: Dong
authors.initials: D
authors.lastname: Young Rhyu
authors.forename: Jeong
authors.initials: J
authors.lastname: Sook Noh
authors.forename: Chul
authors.initials: C
authors.lastname: Min Park
authors.forename: Takako
authors.initials: T
authors.lastname: Yokozawa
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000188:drug therapy* / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D004365:Drugs, Chinese Herbal; C468270:Kangen-karyu